Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes Among Socioeconomically Disadvantaged Communities

Last updated: August 25, 2025
Sponsor: University of Wisconsin, Madison
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetic Vitreous Hemorrhage

Diabetic Macular Edema

Diabetes Prevention

Treatment

AI-BRIDGE

Clinical Study ID

NCT06763952
2024-0030
A536000
Version 8/9/24
1R01EY035994
  • Ages > 22
  • All Genders

Study Summary

This study aims to investigate whether a novel artificial intelligence based screening strategy (AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education or AI-BRIDGE), which allows primary care providers to screen patients for vision-threatening diabetic eye disease in the primary care clinic, improves screening and follow-up care rates across race/ethnicity groups and reduces racial/ethnic disparities in screening.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Eligible patients include patients older than 21 years

  • Diagnosed with type 1 or 2 diabetes

  • No known diabetic eye disease

  • Medicaid as their primary insurance

  • Not had an eye exam in the prior year

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 4000
Treatment Group(s): 1
Primary Treatment: AI-BRIDGE
Phase:
Study Start date:
February 01, 2026
Estimated Completion Date:
May 31, 2029

Study Description

This is a multicenter clinical trial and University of Wisconsin is the coordinating center of the study.

A stepped-wedge cluster randomized clinical trial will be conducted. The investigators will evaluate the effectiveness of two standard diabetic retinopathy screening strategies at primary care clinics; (1) AI-based eye screening program called AI-BRIDGE, eye photos of the patients will be obtained in the primary care clinic by trained clinic staff. Images will be reviewed using autonomous artificial-intelligence (AI) algorithm (Digital Diagnostics). Patients with referrable diabetic retinopathy are detected within minutes and patients with referrable disease will be assisted with scheduling an in-person follow-up eye care visit (2) usual care screening, primary care providers refer patients with diabetes to an eye care provider for an in-person dilated eye exam.

After adapting AI-BRIDGE protocols to clinics and training of clinic personnel, stepped wedge randomized clinical trial begins with sites transitioning from usual-care to AI-BRIDGE in 4 steps.

Primary Objective:

  • Compare the proportion of patients, by race and ethnicity, who follow-up with recommended eye care in the AI-BRIDGE and usual-care arms within 6 months of the recommendation.

Secondary Objectives:

  • Compare the difference in proportion of White vs Hispanic and White vs Black patients who get screening in the AI-BRIDGE and usual-care arms within 6 months of the recommendation.

  • Compare proportion of patients, by race and ethnicity, who receive eye screening in the AI-BRIDGE and usual-care arms within 6 months of the recommendation.

Connect with a study center

  • UW School of Medicine and Public Health

    Madison, Wisconsin 53792
    United States

    Site Not Available

  • UW School of Medicine and Public Health

    Madison 5261457, Wisconsin 5279468 53792
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.